Study summary

The objective of this study was to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in participants with metastatic castration-resistant prostate cancer (mCRPC) known to have risk factor(s) for seizure.

Additional Study Details

Phase
4
Product
  • Enzalutamide
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    424
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English
    Protocol
    Available Language(s): English
    Statistical Analysis Plan (SAP)
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A study to evaluate the potential increased risk of seizures among Metastatic Castration-Resistant Prostate Cancer (mCRPC) patients treated with enzalutamide? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Withdrawn
      Site AU61009
      Wahroonga, NSW, Australia, 2076
      Completed
      Site CA15001
      Quebec City, QC, Canada, G1R3S1
      Completed
      Site SE46002
      Orebro, Sweden, 701 85
      Withdrawn
      Site HU36004
      Miskolc, Borsod-Abauj-Zemplen Megye, Hungary, 3526
      Completed
      Site IL97205
      Haifa, Israel, 31096
      Completed
      Site CZ42004
      Praha 2, Czech Republic, 12000
      Withdrawn
      Site AU61013
      Adelaide, SA, Australia, 5000
      Completed
      Site IT39003
      Roma, Roma, Italy, 00144
      Withdrawn
      Site DE49006
      Tubingen, Baden-Wurttemberg, Germany, 72076
      Completed
      Site CL56004
      Santiago, Chile, 8420383
      Withdrawn
      Site FR33003
      Cannes cedex, France, 06414
      Completed
      Site CA15005
      Abbotsford, BC, Canada, V2S 3N5
      Completed
      Site AU61004
      Ballarat, VIC, Australia, 3350
      Completed
      Site US10026
      Bronx, NY, United States, 10461
      Terminated
      Site FR33005
      Suresnes, France, 92151
      Completed
      Site AU61001
      Tweed Heads, NSW, Australia, 2485
      Withdrawn
      Site CA15007
      Kelowna, BC, Canada, V1W 4V5
      Completed
      Site US10001
      New York, NY, United States, 10065
      Completed
      Site AR54002
      Buenos Aires, CABA, Argentina, C1120AAT
      Completed
      Site IL97208
      Nahariya, Israel, 21000
      Completed
      Site KR82007
      Seoul, Republic of Korea, 03080
      Completed
      Site ES34005
      Sabadell, Barcelona, Spain, 08208
      Completed
      Site ES34006
      Madrid, Madrid, Spain, 28050
      Withdrawn
      Site BE32002
      Roeselare, West-Vlaanderen, Belgium, 8800
      Completed
      Site BE32003
      Liege, Belgium, B-4000
      Withdrawn
      Site GR30001
      Chania, Crete, Greece, 73300
      Withdrawn
      Site NZ64002
      Tauranga, BOP, New Zealand, 3140
      Completed
      Site TW88601
      Kaohsiung, Taiwan, Province of China, 81362
      Withdrawn
      Site HK85201
      Shatin, Hong Kong
      Completed
      Site AU61011
      Sydney, NSW, Australia, 2109
      Completed
      Site IL97206
      Petah-Tiqva, Israel, 49100
      Completed
      Site US10008
      Dallas, TX, United States, 75231
      Completed
      Site CA15010
      Scarborough, ON, Canada, M1S 4V5
      Completed
      Site NZ64001
      Hamilton, New Zealand, 3204
      Completed
      Site HU36002
      Sopron, Gyor-Moson Sopron, Hungary, 9400
      Completed
      Site DE49003
      Berlin, Berlin, Germany, 12200
      Completed
      Site AR54001
      Berazategui, Buenos Aires, Argentina, B1880BBF
      Completed
      Site TW88603
      Taipei City, Taiwan, Province of China, 10048
      Completed
      Site CL56002
      Temuco, Chile, 4781156
      Completed
      Site ES34001
      Pamplona, Navarra, Spain, 31008
      Withdrawn
      Site CA15002
      Toronto, ON, Canada, M5G 2M9
      Completed
      Site AR54006
      Ciudad Autonoma de BuenosAires, Buenos Aires, Argentina, C1426ANZ
      Completed
      Site FR33002
      Lyon Cedex 03, France, 69437
      Withdrawn
      Site HU36001
      Budapest, Pest Megye, Hungary, 1082
      Completed
      Site SG65002
      Singapore, Singapore, 119228
      Completed
      Site US10016
      Durham, NC, United States, 27710
      Completed
      Site AR54004
      Santa Fe, Santa Fe, Argentina, S3000FFU
      Completed
      Site IT39005
      Meldola, Emilia-Romagna, Italy, 47014
      Completed
      Site FI35801
      Oulu, Finland, 90220
      Completed
      Site IL97202
      Kfar Saba, HaMerkaz, Israel, 44281
      Completed
      Site DE49009
      Nürtingen, Baden-Württemberg, Germany, 72622
      Withdrawn
      Site CA15013
      Toronto, ON, Canada, M4N 3M5
      Completed
      Site CL56001
      Temuco, IX Region, Chile, 4810469
      Withdrawn
      Site US10013
      Concord, NC, United States, 28025
      Completed
      Site KR82001
      Seoul, Republic of Korea, 135-720
      Completed
      Site FR33004
      Rouen Cedex, France, 76031
      Completed
      Site ES34003
      Barcelona, Barcelona, Spain, 08025
      Completed
      Site CA15004
      Brampton, ON, Canada, L6T 4S5
      Completed
      Site US10025
      Seattle, WA, United States, 98109
      Completed
      Site AR54005
      Tucuman, Tucuman, Argentina, 4000
      Completed
      Site KR82004
      Seoul, Republic of Korea, 137-701
      Withdrawn
      Site KR82002
      Seoul, Republic of Korea, 120-752
      Completed
      Site DE49001
      Munster, Germany, 48149
      Completed
      Site US10024
      Detroit, MI, United States, 48202
      Completed
      Site GB44002
      Sutton, Surrey, United Kingdom, SM2 5PT
      Completed
      Site US10005
      Anchorage, AK, United States, 99503
      Withdrawn
      Site CA15008
      Toronto, ON, Canada, M6A 3B5
      Completed
      Site IL97203
      Beer-Sheva, Israel, 84101
      Withdrawn
      Site KR82005
      Seoul, Republic of Korea, 138-736
      Withdrawn
      Site US10031
      Lawrenceville, NJ, United States, 08648
      Completed
      Site AU61012
      Kogarah, NSW, Australia, 2217
      Withdrawn
      Site DE49002
      Hamburg, Germany, 22399
      Completed
      Site IT39002
      Arezzo, Arezzo, Italy, 52100
      Completed
      Site CL56003
      Vina del Mar, Chile, 2540364
      Completed
      Site CA15014
      Halifax, NS, Canada, B3H 2Y9
      Withdrawn
      Site DE49005
      Mannheim, Baden-Wurttemberg, Germany, 68167
      Completed
      Site KR82006
      Seongnam-Si, Gyeonggi-do, Republic of Korea, 013620
      Completed
      Site AU61007
      Adelaide, SA, Australia, 5042
      Completed
      Site AU61005
      Randwick, NSW, Australia, 2031
      Completed
      Site SE46001
      Goteborg, Sweden, 41345
      Completed
      Site IT39001
      Cremona, Lombardia, Italy, 26100
      Completed
      Site BE32004
      Anderlecht, Belgium, 1070
      Completed
      Site US10014
      New York, NY, United States, 10065
      Completed
      Site CZ42002
      Praha 6, Czech Republic, 16000
      Completed
      Site AU61002
      Nambour, QLD, Australia, 4560
      Completed
      Site AR54003
      Cordoba, Cordoba, Argentina, 5000
      Completed
      Site IL97201
      Be'er Ya'akov, Israel, 70300
      Withdrawn
      Site US10004
      San Diego, CA, United States, 92123
      Completed
      Site FI35803
      Helsinki, Finland, 00290
      Completed
      Site ES34004
      Barcelona, Barcelona, Spain, 08035
      Withdrawn
      Site DE49004
      Göttingen, Niedersachsen, Germany, 37075
      Completed
      Site IL97204
      Jerusalem, Israel, 91120
      Completed
      Site IL97207
      Ramat Gan, Israel, 52621
      Completed
      Site ES34007
      Hospitalet de Llobregat, Barcelona, Spain, 08908
      Completed
      Site KR82003
      Seoul, Republic of Korea, 135-710
      Withdrawn
      Site US10032
      Albuquerque, NM, United States, 87109
      Completed
      Site US10039
      Syracuse, NY, United States, 13210
      Completed
      Site BE32001
      Kortrijk, Belgium, 8500
      Completed
      Site FI35802
      Tampere, Finland, 33520

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?